Could GLP-1 Medications Help Treat Alcohol Addiction?

GLP-1 people eating and drinking

As an addiction medicine physician, I find these trials fascinating for a reason beyond the drug itself.

We are hearing a lot about the benefits of GLP-1 medications for treating diabetes and supporting weight loss. But could GLP-1 medications eventually help treat alcohol use disorder? We are still early in the research, but the signal is getting interesting. A 2025 randomized trial found that low-dose semaglutide reduced alcohol craving and some measures of drinking in adults with alcohol use disorder. Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus.

A  larger 2026 trial in which 108 people with alcohol use disorder and obesity found greater reductions in heavy drinking days with semaglutide plus cognitive behavioral therapy than with placebo plus therapy. Compared with the placebo, the semaglutide group experienced:

  • Greater reduction in heavy drinking days (heavy drinking defined as 48/60 grams of pure alcohol for women/men)
  • Lower monthly alcohol consumption
  • Fewer drinks on days they drank
  • Reduced alcohol cravings

The important limitation here is that all participants were in larger bodies, so the findings cannot be applied to everyone with an alcohol use disorder. More research is needed.

 

Could GLP-1 Medications Help Treat Alcohol Addiction?

As an addiction medicine physician, I find these trials fascinating for a reason beyond the drug itself. It is another reminder that addiction is deeply connected to reward, appetite, motivation, and behavior in ways we are still striving to understand. These systems help determine what we want, what we seek out, and what we return to again and again. Alcohol activates reward pathways and can reinforce patterns of drinking. Over time, familiar people, places, and things can trigger a powerful desire to drink alcohol, even when an individual wants to stop.

GLP-1 medications modulate appetite and also act on the reward pathways. Researchers are investigating whether those effects could reduce alcohol cravings and alcohol consumption. Early clinical findings suggest some people experience fewer cravings and reductions in drinking, although questions remain. Reducing the intensity of a craving may give people more room to develop coping skills, change routines, and engage in successful addiction treatment.

 

Watch This Space!

I would not put GLP-1s in the standard addiction medicine toolbox yet. The studies are still small. We need larger trials, longer follow-up, and a much better understanding of who is most likely to benefit. But I would absolutely keep watching this space. Addiction medicine has had a relatively limited medication toolkit for a long time. If GLP-1 therapies continue to show meaningful effects, they could eventually give us another option for patients who need more than what we can offer today.

 

If you or a loved one is struggling with a mental health condition, including addiction and eating disorders, click the link below to speak with an admissions specialist today. Experience 24/7 EZ Admissions: talk to a real person, get a free assessment, and start treatment 24 hours a day, 7 days a week. Walk-ins welcome.

 

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. 

All trademarks and logos are the property of their respective owners. Insurance coverage varies by plan; please contact your provider to verify benefits. 

Medical services provided by Sanford Medical Specialists, PLLC. 

Sanford Chief Medical Officer, Dr. Bibhas Singla, is triple board-certified in Psychiatry, Addiction Medicine, and HALM (Healthcare Administration, Leadership, and Management). He also holds industry distinctions as a FACHE (Fellow of the American College of Healthcare Executives), CPE (Certified Physician Executives), and FAPA (Fellow of the American Psychiatric Association). He has more than 15 years of experience in behavioral health, specializing in addiction treatment. Dr. Singla has cared for patients across acute, residential, and outpatient settings. He has also worked with payers and policymakers to expand access to mental health services. Look for his article series in the new year!